Investing.com - FibroGen Inc (NASDAQ: FGEN) reported first quarter EPS of $-0.330, $0.08 better than the analyst estimate of $-0.410. Revenue for the quarter came in at $55.9M versus the consensus estimate of $36.45M.
Guidance
FibroGen Inc sees FY 2024 revenue of $120.000M-$135.000M versus the analyst consensus of $155.300M.
FibroGen Inc's stock price closed at $1.16. It is down -51.260% in the last 3 months and down -93.160% in the last 12 months.
FibroGen Inc saw 2 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See FibroGen Inc's stock price’s past reactions to earnings here.
According to InvestingPro, FibroGen Inc's Financial Health score is "weak performance".
Check out FibroGen Inc's recent earnings performance, and FibroGen Inc's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar